Quick Answer
Nurix Therapeutics, Inc. reported R&D Expense of $316.90 million for fiscal year 2025.
Nurix Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $316.90M | +43.0% |
| 2024 | $221.63M | +17.2% |
| 2023 | $189.15M | +2.5% |
| 2022 | $184.50M | +58.5% |
| 2021 | $116.43M | +75.1% |
| 2020 | $66.49M | +47.7% |
| 2019 | $45.02M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | $86.12M | +55.2% | +10.3% |
| May 31, 2025 | $78.10M | +59.6% | +12.1% |
| February 28, 2025 | $69.66M | +39.3% | +25.6% |
| August 31, 2024 | $55.48M | +15.9% | +13.4% |
| May 31, 2024 | $48.92M | +6.9% | -2.2% |
| February 29, 2024 | $50.01M | +9.1% | +4.5% |
| August 31, 2023 | $47.86M | +0.2% | +4.6% |
| May 31, 2023 | $45.76M | -3.6% | -0.1% |
- Nurix Therapeutics, Inc. showed an increase of +43.0% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Nurix Therapeutics, Inc.’s r&d expense has grown by 603.8% (from $45.02 million to $316.90 million).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: